Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Paying user area

Try for free

Celgene Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Celgene Corp., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Short-term borrowings and current portion of long-term debt
Accounts payable
Rebates, distributor chargebacks and distributor services
Compensation
Clinical trial costs and grants
Litigation-related loss contingency
Interest
Sales, use, value added, and other taxes
Milestones payable
Success payment liability
Short-term contingent consideration and success payments
Royalties, license fees and collaboration agreements
Deferred tax liability
Other
Accrued expenses and other current liabilities
Income taxes payable
Current portion of deferred revenue
Current liabilities
Deferred revenue, net of current portion
Income taxes payable
Deferred income tax liabilities
Other non-current tax liabilities
Contingent consideration
Deferred compensation and long-term incentives
Contingent value rights
Derivative contracts
Other
Other non-current liabilities
Long-term debt, net of discount, excluding current portion
Non-current liabilities
Total liabilities
Preferred stock, $.01 par value per share; none outstanding
Common stock, $.01 par value per share
Common stock in treasury, at cost
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Celgene Corp. current liabilities increased from 2016 to 2017 and from 2017 to 2018.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Celgene Corp. non-current liabilities increased from 2016 to 2017 and from 2017 to 2018.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Celgene Corp. total liabilities increased from 2016 to 2017 and from 2017 to 2018.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Celgene Corp. stockholders’ equity increased from 2016 to 2017 but then decreased significantly from 2017 to 2018.